A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Meric-Bernstam, F.; Gordon, M.; Tykodi, S.; Lam, E.; Vaishampayan, U.; Chaves, J.; Nikolinakos, P.; Fan, A.; Lee, R.; McDermott, D.; Shapiro, G.; Gandhi, L.; Tawbi, H.; Bhatia, S.; Muigai, L.; Jenkins, Y.; Whiting, S.; Voss, M. |
| Abstract Title: | A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC) |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 86 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0289-3 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: O16 |
